A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

S. B. Cohen, L. W. Moreland, J. J. Cush, M. W. Greenwald, S. Block, W. J. Shergy, P. S. Hanrahan, M. M. Khraishi, A. Patel, G. Sun, M. B. Bear

Research output: Contribution to journalArticle

233 Citations (Scopus)

Abstract

Objective: To assess the efficacy and safety of 100 mg daily anakinra (Kineret), a recombinant form of the naturally occurring interleukin 1 receptor antagonist, plus methotrexate (MTX) in reducing the signs and symptoms of rheumatoid arthritis (RA). Methods: Patients with active RA (n = 506) despite current treatment with MTX were enrolled in this multicentre, double blind, randomised, placebo controlled study. Patients received subcutaneous injections of anakinra 100 mg/day or placebo. They were assessed monthly for 6 months for improvement in signs and symptoms of RA and for adverse events. The primary efficacy measure was the percentage of patients attaining ACR20 response at week 24. Results: Significantly greater proportions of patients treated with anakinra compared with placebo achieved ACR20 (38% v 22%; p<0.001), ACR50 (17% v 8%; p<0.01), and ACR70 (6% v 2%; p<0.05) responses. The response to anakinra was rapid; the proportion of patients with an ACR20 response at the first study assessment (4 weeks) was twice as high with anakinra as with placebo (p<0.005). Clinically meaningful and statistically significant responses were also seen in individual components of the ACR response (for example, Health Assessment Questionnaire, pain, C reactive protein levels, and erythrocyte sedimentation rate). Anakinra was well tolerated, with a safety profile, similar to that of placebo with one exception: mild to moderate injection site reactions were more common with anakinra than with placebo (65% v 24%). Conclusions: This study confirms previous observations from a dose-ranging study showing that anakinra, in combination with MTX, is an effective and safe treatment for patients with RA who have inadequate responses to MTX alone.

Original languageEnglish (US)
Pages (from-to)1062-1068
Number of pages7
JournalAnnals of the Rheumatic Diseases
Volume63
Issue number9
DOIs
StatePublished - Sep 1 2004
Externally publishedYes

Fingerprint

Interleukin 1 Receptor Antagonist Protein
Interleukin-1 Receptors
Methotrexate
Rheumatoid Arthritis
Randomized Controlled Trials
Placebos
Signs and Symptoms
Safety
Blood Sedimentation
Pain Measurement
Subcutaneous Injections
Sedimentation
C-Reactive Protein
Health

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. / Cohen, S. B.; Moreland, L. W.; Cush, J. J.; Greenwald, M. W.; Block, S.; Shergy, W. J.; Hanrahan, P. S.; Khraishi, M. M.; Patel, A.; Sun, G.; Bear, M. B.

In: Annals of the Rheumatic Diseases, Vol. 63, No. 9, 01.09.2004, p. 1062-1068.

Research output: Contribution to journalArticle

Cohen, S. B. ; Moreland, L. W. ; Cush, J. J. ; Greenwald, M. W. ; Block, S. ; Shergy, W. J. ; Hanrahan, P. S. ; Khraishi, M. M. ; Patel, A. ; Sun, G. ; Bear, M. B. / A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. In: Annals of the Rheumatic Diseases. 2004 ; Vol. 63, No. 9. pp. 1062-1068.
@article{8e736a1844c74cc694e43e849b163487,
title = "A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate",
abstract = "Objective: To assess the efficacy and safety of 100 mg daily anakinra (Kineret), a recombinant form of the naturally occurring interleukin 1 receptor antagonist, plus methotrexate (MTX) in reducing the signs and symptoms of rheumatoid arthritis (RA). Methods: Patients with active RA (n = 506) despite current treatment with MTX were enrolled in this multicentre, double blind, randomised, placebo controlled study. Patients received subcutaneous injections of anakinra 100 mg/day or placebo. They were assessed monthly for 6 months for improvement in signs and symptoms of RA and for adverse events. The primary efficacy measure was the percentage of patients attaining ACR20 response at week 24. Results: Significantly greater proportions of patients treated with anakinra compared with placebo achieved ACR20 (38{\%} v 22{\%}; p<0.001), ACR50 (17{\%} v 8{\%}; p<0.01), and ACR70 (6{\%} v 2{\%}; p<0.05) responses. The response to anakinra was rapid; the proportion of patients with an ACR20 response at the first study assessment (4 weeks) was twice as high with anakinra as with placebo (p<0.005). Clinically meaningful and statistically significant responses were also seen in individual components of the ACR response (for example, Health Assessment Questionnaire, pain, C reactive protein levels, and erythrocyte sedimentation rate). Anakinra was well tolerated, with a safety profile, similar to that of placebo with one exception: mild to moderate injection site reactions were more common with anakinra than with placebo (65{\%} v 24{\%}). Conclusions: This study confirms previous observations from a dose-ranging study showing that anakinra, in combination with MTX, is an effective and safe treatment for patients with RA who have inadequate responses to MTX alone.",
author = "Cohen, {S. B.} and Moreland, {L. W.} and Cush, {J. J.} and Greenwald, {M. W.} and S. Block and Shergy, {W. J.} and Hanrahan, {P. S.} and Khraishi, {M. M.} and A. Patel and G. Sun and Bear, {M. B.}",
year = "2004",
month = "9",
day = "1",
doi = "10.1136/ard.2003.016014",
language = "English (US)",
volume = "63",
pages = "1062--1068",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "9",

}

TY - JOUR

T1 - A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

AU - Cohen, S. B.

AU - Moreland, L. W.

AU - Cush, J. J.

AU - Greenwald, M. W.

AU - Block, S.

AU - Shergy, W. J.

AU - Hanrahan, P. S.

AU - Khraishi, M. M.

AU - Patel, A.

AU - Sun, G.

AU - Bear, M. B.

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Objective: To assess the efficacy and safety of 100 mg daily anakinra (Kineret), a recombinant form of the naturally occurring interleukin 1 receptor antagonist, plus methotrexate (MTX) in reducing the signs and symptoms of rheumatoid arthritis (RA). Methods: Patients with active RA (n = 506) despite current treatment with MTX were enrolled in this multicentre, double blind, randomised, placebo controlled study. Patients received subcutaneous injections of anakinra 100 mg/day or placebo. They were assessed monthly for 6 months for improvement in signs and symptoms of RA and for adverse events. The primary efficacy measure was the percentage of patients attaining ACR20 response at week 24. Results: Significantly greater proportions of patients treated with anakinra compared with placebo achieved ACR20 (38% v 22%; p<0.001), ACR50 (17% v 8%; p<0.01), and ACR70 (6% v 2%; p<0.05) responses. The response to anakinra was rapid; the proportion of patients with an ACR20 response at the first study assessment (4 weeks) was twice as high with anakinra as with placebo (p<0.005). Clinically meaningful and statistically significant responses were also seen in individual components of the ACR response (for example, Health Assessment Questionnaire, pain, C reactive protein levels, and erythrocyte sedimentation rate). Anakinra was well tolerated, with a safety profile, similar to that of placebo with one exception: mild to moderate injection site reactions were more common with anakinra than with placebo (65% v 24%). Conclusions: This study confirms previous observations from a dose-ranging study showing that anakinra, in combination with MTX, is an effective and safe treatment for patients with RA who have inadequate responses to MTX alone.

AB - Objective: To assess the efficacy and safety of 100 mg daily anakinra (Kineret), a recombinant form of the naturally occurring interleukin 1 receptor antagonist, plus methotrexate (MTX) in reducing the signs and symptoms of rheumatoid arthritis (RA). Methods: Patients with active RA (n = 506) despite current treatment with MTX were enrolled in this multicentre, double blind, randomised, placebo controlled study. Patients received subcutaneous injections of anakinra 100 mg/day or placebo. They were assessed monthly for 6 months for improvement in signs and symptoms of RA and for adverse events. The primary efficacy measure was the percentage of patients attaining ACR20 response at week 24. Results: Significantly greater proportions of patients treated with anakinra compared with placebo achieved ACR20 (38% v 22%; p<0.001), ACR50 (17% v 8%; p<0.01), and ACR70 (6% v 2%; p<0.05) responses. The response to anakinra was rapid; the proportion of patients with an ACR20 response at the first study assessment (4 weeks) was twice as high with anakinra as with placebo (p<0.005). Clinically meaningful and statistically significant responses were also seen in individual components of the ACR response (for example, Health Assessment Questionnaire, pain, C reactive protein levels, and erythrocyte sedimentation rate). Anakinra was well tolerated, with a safety profile, similar to that of placebo with one exception: mild to moderate injection site reactions were more common with anakinra than with placebo (65% v 24%). Conclusions: This study confirms previous observations from a dose-ranging study showing that anakinra, in combination with MTX, is an effective and safe treatment for patients with RA who have inadequate responses to MTX alone.

UR - http://www.scopus.com/inward/record.url?scp=3442885115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3442885115&partnerID=8YFLogxK

U2 - 10.1136/ard.2003.016014

DO - 10.1136/ard.2003.016014

M3 - Article

C2 - 15082469

AN - SCOPUS:3442885115

VL - 63

SP - 1062

EP - 1068

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 9

ER -